Skip to main content
NewslettersWatchlist

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update

Antibe Therapeutics Inc

15 Prince Arthur Avenue
Toronto ON M5R 1B2 CAN
P: 905-570-5103
https://www.antibethera.com

Sectors & Indices

Sector
Industry
Employees

    Profile

    Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

    Key Executives

    NameTitle
    Joseph StaufferChief Medical Officer
    Daniel LegaultCEO/Director/President/Secretary
    David VaughanOther Executive Officer
    Alain WilsonCFO
    Scott CurtisCOO/Executive VP
    Ana StegicOther Corporate Officer
    Christina CameronVice President, Divisional
    Ella Korets-SmithVice President, Divisional
    Philip SternVice President, Divisional

    More from The Globe

    Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
    Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
    Premarket: U.S. futures extend losses after economic data
    A trader works on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24, 2024, in New York. (AP Photo/Mary Altaffer)
    Fiera Capital’s largest shareholder looks to sell stake in company
    Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
    The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
    The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
    The close: Stocks higher as investors digest earnings
    Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 20, 2024.
    The close: Stocks higher with major corporate earnings on tap
    A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 5.
    If pension funds can’t see the case for investing in Canada, why should you?
    Ian McGugan
    the rob interview
    Head in the cloud: How Cisco CEO Chuck Robbins is reviving a Silicon Valley icon
    Cisco CEO Chuck Robbins, seen in Toronto on Oct. 12, is a 6-foot-4 former college basketball player and 20-year veteran of the company. He steps into what no one would describe as a dream job: a lengthy slog to direct a one-time Silicon Valley star through its challenging next chapter.

    All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

    Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

    Financial data provided by Zacks Investment Research.